XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

Abstract The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated modest anti-DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL patients and the rational combination therapies in high-risk DLBCL. High XPO1 express...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Manman Deng, Mingzhi Zhang, Zijun Y. Xu-Monette, Lan V. Pham, Alexandar Tzankov, Carlo Visco, Xiaosheng Fang, Govind Bhagat, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, William W. L. Choi, Jooryung Huh, Maurilio Ponzoni, Andrés J. M. Ferreri, Michael B. Møller, Benjamin M. Parsons, J. Han van Krieken, Miguel A. Piris, Jane N. Winter, Fredrick Hagemeister, Lapo Alinari, Yong Li, Michael Andreeff, Bing Xu, Ken H. Young
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMC 2020-11-01
Cyfres:Journal of Hematology & Oncology
Pynciau:
XPO1
DLBCL
HGBCL
TP53 mutation
Selinexor
MYC
Mynediad Ar-lein:http://link.springer.com/article/10.1186/s13045-020-00982-3
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg